Introduction
Acenocoumarol and warfarin are oral anticoagulants of the family of vitamin K antagonists. They are the most prescribed in the prevention and treatment of arterial and venous thromboembolic illnesses (1) . Interindividual variation in response to therapy constitutes a serious problem for determining the appropriate vitamin K antagonists dose (2) . This variability is known to depend on many environmental and non-genetic factors; nevertheless a genetic factor has also been reported to play an important role in the variability of the appropriate dose and antivitamin K drug metabolism (3) (4) (5) (6) (7) .
Two genes identified as cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) are mostly described to influence the pharmacokinetic and pharmacodynamic parameters of vitamin K antagonists (6, (8) (9) (10) (11) . CYP2C9 is the main enzyme responsible for the biotransformation and subsequent elimination of vitamin K antagonists (11, 12) . Available data indicate that the CYP2C9 is polymorphic (3 major alleles: CYP2C9*1 wild-type allele, CYP2C9*2 and CYP2C9*3 variant alleles), and its genetic variability has been reported to be related with variations in the levels of enzyme activity (12) (13) (14) . The two defective alleles CYP2C9*2 and CYP2C9*3 were characterized as slow metabolizers and known to be strongly associated with dose requirement and bleeding complications of vitamin K antagonist (12) (13) (14) (15) (16) (17) . VKORC1 code for the target enzyme of coumarins (18) (19) (20) . Vitamin K antagonists exert its effect through inhibition of the VKORC1 gene product. Genetic variations within VKORC1 result in changed sensitivity to vitamin K antagonists. Available data indicate that the single nucleotide polymorphism (SNP) in the promoter region at the nucleotide position -1639 G>A for VKORC1 gene and there intronic polymorphism 1173 C>T were found to be strongly affecting vitamin K antagonists dosage (21) . These SNPs were found to be in linkage disequilibrium (22) . Patients carrying the wild type G allele for the VKORC1 -1639 G>A required a higher dose of vitamin K antagonists compared with those carrying the A variant allele (23) . Also, patients carrying the wild type C allele for VKORC1 1173 C>T required a higher dose of vitamin K antagonists compared with those carrying the variant T allele (24) .
Recently, the genes of cytochrome P450 4F2 (CYP4F2) and gamma glutamyl carboxylase (GGCX) also contributed moderately to the variability of vitamin K antagonists dose estimated between 1-2% in Caucasian patients (25, 26) . CYP4F2 gene encodes an enzyme that metabolizes vitamin K1 to hydroxyvitamin K1 (25) . Whereas GGCX is the enzyme responsible for gamma carboxylation of vitamin K-dependent proteins (27) .
Acenocoumarol is mostly prescribed in Europe and Africa. Many works have been undertaken to study the implication of the genetic polymorphism of the CYP2C9 and VKORC1 on inter-individual acenocoumarol dose variability. In Morocco, acenocoumarol is the only one vitamin K antagonist drug that has had its marketing authorization. However, only a few small studies have investigated the contribution of the non-genetic factors, CYP4F2, CYP2C9 and VKORC1 -1639 G>A polymorphisms on acenocoumarol dose requirements (28, 29) . And little information is available on the possible implication of VKORC1 1173 or GGCX SNPs on the subject in our country. The aim of this study was to evaluate the influence of non-genetic and CYP2C9, VKORC1 -1639, VKORC1 1173, CYP4F2 and GGCX polymorphisms on acenocoumarol maintenance dose in a cohort of Moroccan adult patients, in order to develop a useful algorithm for predicting anticoagulant dose for Moroccan patients.
Materials and Methods

Ethic statement
Ethical approval for this study was obtained from the Biomedical Research Ethics Committee of the Faculty of Medicine and Pharmacy of Rabat, Mohamed V University, Morocco following the guidelines set by the Declaration of Helsinki. For each patient, an information sheet has been completed with epidemiological data. Written informed consent was obtained from all patients after being informed of the purpose of our work.
Patients and sample collection
A total of 217 patients from different regions of Morocco were recruited in this study. They were registered between January 2015 to December 2016 in the various clinical departments of the Mohamed V Military Teaching Hospital (MVMTH) at Rabat for the surveillance of Thromboembolic (TE) disease, atrial fibrillation (AF) or heart valves. Patients were 17 years or older and were taking a maintenance dose of acenocoumarol to maintain an International Normalized Ratio (INR) of 2.0-3.0.
Cases were defined as those whose acenocoumarol dose requirement has retained constant for at least four successive clinic visits. All these patients are referred to the laboratory of Hematology in the MVMTH for the realization of the prothrombin time (PT)/INR analysis. Upon arrival at the Laboratory, a blood sample was collected (4 mL) into a sterile EDTA vacutainer and stored at 4°C until further processing for DNA extraction, and a sample was collected in a sterile citrate vacutainer for INR assessment. Both samples were collected in the same visit; the INR sample was processed on the same day while the DNA samples were referred for genetic testing in the Laboratory of Medical Biotechnology, Faculty of Medicine and Pharmacy of Rabat.
Patients who were on concomitant therapy with drugs potentially interacting with acenocoumarol, patients with abnormal blood tests of renal or hepatic function; lacting women and alcoholics were excluded from the study.
DNA extraction
DNA was extracted from blood samples using the QIAamp DNA Blood Extraction Kit according to the manufacturer's instructions (Qiagen, Germany). DNA was quantified by NanoDrop Analyser (ND 1000) spectrophotometer (NanoDrop Technologies, Wilmington, USA). The ratio of absorbance at 260 and 280 nm of DNA was between 1.7 and 1.9.
Amplification and purification
Amplification reaction of each VKORC1 -1639 G>A, VKORC1 1173 C>T, CYP2C9*2, CYP2C9*3, CYP4F2 1347 G>A and GGCX 12970 C>G SNPs was carried equilibrium was determined using a web-based calculator available at (https://www.snpstats.net/ snpstats/start.htm) (30) . The effect of non-genetic and genetic variants on the mean acenocoumarol dose was calculated by univariate analysis using appropriate test depending on the nature of the variables compared. Kruskal-Wallis or Mann-Whitney test was used for non-parametric analysis where appropriate. For all statistical tests, the significance level was set at 0.05. A multiple linear regression analysis was used to assess the ability of age, VKORC1 (1173) and (1639) genotypes and CYP2C9 haplotype to predict the dose of acenocoumarol in order to propose to clinicians an algorithm taking into account all these variables.
Results
Patients characteristics
Two hundred and seventeen patients, receiving stable dose of acenocoumarol treatment, were included in this study. The average age of the study populations was 57 ± 14 years (17-87 years old), the sex-ratio was 0.95 (111 females and 106 males), and the mean of acenocoumarol maintenance dose was 22.94 ± 12.01 mg/week. The characteristics of the included patients are summarized in the Table 2 . Genotypic frequencies of all genes assessed in this study are given in Table  3 . Allelic frequencies for the all assessed SNPs were found to be in Hardy-Weinberg equilibrium (p > 0.05) (data not shown). out using the Master Mix 2X (Bioline, London, UK), 400 nM of each appropriate primers (Eurogentec, Belgium) (Table 1) , and 60 ng of template DNA in a 25 µL reaction volume under the following conditions: preheating at 95°C for 3 min, then 35 cycles of (95°C, 30 s; 58°C, 30 s; 72°C, 30 s), followed by final extension of 5 min at 72°C employing a thermal cycler. The PCR amplicons of VKORC1, CYP2C9, and CYP4F2 gene were electrophoresed on a 3% agarose gel and on a 1% agarose gel for GGCX gene.
Genotyping
After the PCR reaction, the amplification products were purified using ISOLATE II PCR and Gel Kit according to the manufacturer's instructions (Bioline, London, UK). The purified amplicons were genotyped for all investigated SNPs using Restriction Fragment length Plymorphism (RFLP) technique. So, the purified amplicons was digested with 2 units of restriction enzyme (Biolabs, New England) overnight at 37°C. The digested products were analyzed on 3% agarose gel except for GGCX 12970 C>G polymorphism who were separated on 2% agarose gel. The restriction enzymes used for each SNP and the size of digested products are summarized in Table 1 .
Statistical analysis
Statistical analysis was performed using SPSS software (Version 18) under windows. Hardy Weinberg 
GGCX (12970 C>G)
Primer sequences 
Association of non-genetic factors with acenocoumarol dose
The associations between age, sex, body mass index (BMI), ethnic origin, acenocoumarol therapy indication, duration of therapy, medications, the good diet monitoring and Acenocoumarol weekly dose were studied (Table 2 ). Univariate analysis showed that the age was the only one non-genetic factor significantly associated with the acenocoumarol weekly maintenance dose (p = 0.023) ( Table 2) . Patients up to 65 years (17.41 ± 10.80 mg/week) of age required a lower dose compared to the patients under 65 years old (25.25 ± 11.76 mg/week) (data not showed). (Table  3) .
There was no association found between the weekly acenocoumarol dose and the CYP4F2 or GGCX variants (p-value > 0.05) ( Table 3) .
Cumulate effect of VKORC1 and CYP2C9 polymorphisms on acenocoumarol dose
The relationship between the three polymorphisms of each two SNPs of VKORC1 gene (-1639 and 1173) and VKORC1 -1639 or VKORC1 1173 variants with (Table 7) .
From the data in Table 7 , the proposed regression equation to predict weekly dose (WD) of acenocoumarol for our final Model was:
Log ( 
Discussion
The aim of this study was to investigate the impact of non-genetics factors and VKORC1, CYP2C9, CYP4F2, and GGCX polymorphisms on acenocoumarol maintenance dose in a cohort of Moroccan patients. Acenocoumarol is the only one coumarin anticoagulants available for the treatment and prevention of thromboembolic diseases in Morocco. Several factors have been described to influence the individual sensitivity for anticoagulant therapy. Genetic factors, mostly SNP variations in CYP2C9 and VKORC1, in association with non-genetic factors have been reported to account for 60% of the variation in vitamin K antagonists dosage (6) . In our analysis, the age was the only one non-genetic factor significantly associated with the acenocoumarol dose and the required dose was significantly lower when age was increased. However, many studies have reported that the acenocoumarol and warfarin dose was influenced by other demographic factors such as gender, body mass index and ethnicity (6, 23) .
Our study showed a significant association between genetic polymorphisms in VKORC1 and CYP2C9 and acenocoumarol dose requirement, and corroborating with the findings reported in other countries including Morocco (6) (7) (8) (9) (10) (11) (12) (13) (14) 17, 21, 23, 28, 29) .
Several studies published in the world show that VKORC1 -1639 G>A, VKORC1 1173 C>T, CYP2C9*2 Table 7 . Multiple regression models considering log-transformation the weekly dose of AC as dependent variable and CYP2C9*3 were the most significant SNPs to affect vitamin K antagonists dosage (6) (7) (8) (9) (10) (11) (12) (13) (14) 17, 21, 23, 28, 29 (23) . Similar percentages were found in Caucasian patients (25% and 50% less doses, respectively), while in Asian patients the percentages were lower (14% and 38%, respectively). According to the previous studies investigated the effect of VKORC1 -1639 polymorphisms on VKORC1 expression, homozygotes for the G allele have a higher transcription activity of 44 % than those homozygote for the A allele (31) . Therefore, homozygotes for the A allele would have lower levels of VKORC1 expression and logically would require a lower concentration of acenocoumarol, as is the case in our study.
To our knowledge, this is the first study that reports the effect of genetic polymorphisms of the VKORC1 1173 C>T SNP in the variability to the acenocoumarol response among Moroccan population.
VKORC1 1173 CC genotype was associated with a significantly higher acenocoumarol dose when compared to both the CT heterozygous genotype and the TT variant genotype. Patients carrying CT or TT genotypes required a 39.80% and 48.53% less dose, respectively, compared to patients with a wild genotype (CC genotype). These results are demonstrated in other countries using acenocoumarol, in the German and Austrian populations (25% and 52%) (32) , in Dutch patients (28% and 47%) (24) , and in Chinese patients (33% and 55%) (33) .
Like Warfarin, acenocoumarol is metabolized by CYP2C9. It has been identified that CYP2C9*2 and CYP2C9*3 variants alleles reduce in vitro enzymatic activity. Therefore, patients carrying heterozygous and homozygous variants CYP2C9 alleles were more sensitive to vitamin K antagonists therapy and present a higher risk of bleeding complications than patients carrying the CYP2C9*1 alleles (34). Here, patients with one CYP2C9 variant allele (*1/*2 or *1/*3) required a 23.95% less dose and patients with two variant alleles (*2/*2, *2/*3) a 33.61% less dose than patients without this variant allele (*1/*1). These results correlate with previous findings indicating that acenocoumarol dose requirement is 19-29% less in carriers one or two CYP2C9 variant allele than in wild-types (35) .
The data reported by Smires et al. has shown that, there was no association between the acenocoumarol dose variation and the CYP4F2 polymorphisms among Moroccan population (28) . Although, the CYP4F2 variant allele (A) frequency was of 37% (Table 3) , our findings support this fact and confirm that the required acenocoumarol dose, is probably not affected by the modification of the CYP4F2 gene in the Moroccan population.
This study is the first in Morocco to assess whether the genetic polymorphisms of GGCX SNP influences the individual response for AC therapy. However, our results shown that there was no association between GGCX polymorphisms and acenocoumarol dose maintenance.
The GGCX wild type allele (C) was found in a very higher frequency (97%) in our study samples (Table 3) . It's known that ethnic differences in allelic frequencies of SNPs implicated in vitamin K antagonists dose variability affect the sensitivity to treatment among different population (36) . Thus, we can't confirm that the lower frequency of GGCX variant allele (G) was responsible for such a result.
However, a large and representative investigation is necessary to better evaluate the effect of CYP4F2 and GGCX SNPs on the acenocoumarol dose assessment among Moroccan population.
Similar to the results from other studies (12, 37) , non-parametric analysis based on acenocoumarol dose, VKORC1 -1639, VKORC1 1173 SNPs and CYP2C9 haplotypes demonstrated that these three SNPs exert a cumulative effect on the acenocoumarol dose requirement. Patients carrying homozygous variant alleles at VKORC1 -1639 (AA) and VKORC1 1173 (TT) SNPs required 59.75% less dose than wild type for the two SNPs. Carriers VKORC1 -1639 AA and CYP2C9 *x/*x genotypes required 78.42% less dose than VKORC1 -1639 GG and CYP2C9 *1/*1 genotypes. The single patient who had VKORC1 -1173 TT variant and CYP2C9 *x/*x haplotype (CYP2C9 *2/*2 or *2/*3) had the lowest weekly AC dose (4 mg/week) among the all investigated patients (90.24% less dose).
As reported in other investigations (33, (38) (39) (40) , the multiple linear regression analysis confirmed that VKORC1 and CYP2C9 contribute mainly to the interindividual variability of the acenocoumarol dose requirement. As shown by the results of this and other studies (6) (7) (8) (9) (10) (11) (12) (13) (14) 17, 21, 23, 28, 29) , the variation in acenocoumarol dose response is partially influenced by the differences in genetic polymorphisms, especially in CYP2C9 and VKORC1. Therefore, our proposed regression equation might be useful to Moroccan clinician physicians for initial determination of acenocoumarol dose. The effectiveness of this equation should be evaluated in a future study.
In conclusion, the present study confirmed that the high variability in the maintenance dose of acenocoumarol in Moroccan populations is related to demographic factors and genetic factors, in particular VKORC1 -1639, VKORC1 1173, CYP2C9*2 and CYP2C9*3. In addition, acenocoumarol susceptibility was shown to be higher in patients with one or more mutations in these SNP. The presence of these mutations indicates that a lower initial dose of acenocoumarol should be used to reduce the risk of bleeding. Furthermore, this study provides a useful model for predicting the weekly dose of acenocoumarol for Moroccan patients based on their genetic makeup. 
